{"id":"NCT02023268","sponsor":"Laboratoires Thea","briefTitle":"Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome","officialTitle":"Phase III: Comparison of the Efficacy and Safety of T2762 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12","primaryCompletion":"2014-12","completion":"2015-02","firstPosted":"2013-12-30","resultsPosted":"2016-04-06","lastUpdate":"2017-08-24"},"enrollment":105,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DEVICE","name":"T2762","otherNames":[]},{"type":"DEVICE","name":"Vismed®","otherNames":[]}],"arms":[{"label":"T2762","type":"EXPERIMENTAL"},{"label":"Vismed®","type":"ACTIVE_COMPARATOR"}],"summary":"Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome","primaryOutcome":{"measure":"Global Ocular Staining (With Oxford Scale - Ranges : 0-15)","timeFrame":"Baseline and Day 35","effectByArm":[{"arm":"T2762","deltaMin":-2.5,"sd":2},{"arm":"Vismed","deltaMin":-2.7,"sd":1.7}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":1,"countries":["France"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":[]}}